Valuation: IDEAYA Biosciences, Inc.

Market Cap 3.16B 2.86B 2.64B 2.39B 4.51B 297B 4.65B 31.69B 12.6B 159B 11.87B 11.62B 506B P/E 2026 *
-6.83x
P/E 2027 * -7.46x
Enterprise Value 2.15B 1.94B 1.79B 1.62B 3.06B 202B 3.15B 21.51B 8.55B 108B 8.06B 7.89B 343B EV / Sales 2026 *
50.6x
EV / Sales 2027 * 16.9x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
1 day-3.65%
1 week+3.52%
Current month-0.72%
1 month-12.01%
3 months-14.15%
6 months+12.84%
Current year-8.22%
1 week 30.45
Extreme 30.45
32.91
1 month 30.45
Extreme 30.45
36.35
Current year 26.81
Extreme 26.81
42.68
1 year 26.81
Extreme 26.81
42.68
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Director of Finance/CFO 51 2025-04-30
Chief Tech/Sci/R&D Officer 59 2022-11-20
Director TitleAgeSince
Chairman 51 2026-06-16
Chairman 67 -
Director/Board Member 71 2015-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Exercice

Chief Executive Officer

79,014 0.0902%
7/7/26 Exercice

Controller/Auditor

28,650 0.0327%
6/16/26 Free

Director

20,000 0.0228%
Change 5-day change 1-year change 3-year change Capi.($)
-3.79%+3.52%-0.69%+8.66% 3.16B
+1.10%+1.03%+62.53%+70.47% 67.53B
+1.28%+8.71%+13.96%+92.70% 60.74B
+0.36%-0.95%+20.09%+98.45% 55.66B
-0.41%+8.58%+11.39%+111.46% 47.97B
-1.24%+2.37%+22.76%+40.01% 45.24B
-2.08%-0.19%+169.36%+802.39% 39.08B
+1.21%+4.75%+27.30%+52.81% 35.34B
-0.87%-2.89%+79.60%+56.33% 33.45B
-2.30%+8.89%-39.08%+395.52% 26.49B
Average -0.62%+2.54%+36.72%+172.88% 41B
Weighted average by Cap. -0.06%+2.87%+40.93%+165.53%

Financials

2026 *2027 *
Net sales 42.4M 38.35M 35.4M 32.04M 60.46M 3.99B 62.27M 425M 169M 2.13B 159M 156M 6.78B 124M 113M 104M 94.03M 177M 11.7B 183M 1.25B 496M 6.25B 467M 457M 19.91B
Net income -463M -419M -387M -350M -661M -43.56B -680M -4.64B -1.84B -23.29B -1.74B -1.7B -74.12B -452M -409M -378M -342M -645M -42.53B -664M -4.53B -1.8B -22.73B -1.7B -1.66B -72.36B
Net Debt -1.02B -919M -849M -768M -1.45B -95.57B -1.49B -10.19B -4.05B -51.09B -3.82B -3.73B -163B -1.06B -956M -883M -799M -1.51B -99.41B -1.55B -10.59B -4.21B -53.15B -3.97B -3.88B -169B
Projected Income Statement - Annual - IDEAYA Biosciences, Inc.
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
26-11-12 US$31.65 -3.26% 273,437
26-11-11 US$32.72 +3.04% 793,859
26-11-10 US$31.75 -0.87% 950,300
26-11-09 US$32.03 +2.53% 884,957
26-11-06 US$31.24 +1.92% 1,652,527
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - IDEAYA Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
32.72USD
Average target price
50.69USD
Spread / Average Target
+54.95%
  1. Stock Market
  2. Stocks
  3. IDYA Stock